These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 33809178)
1. Mycobacterial Epoxide Hydrolase EphD Is Inhibited by Urea and Thiourea Derivatives. Madacki J; Kopál M; Jackson M; Korduláková J Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809178 [TBL] [Abstract][Full Text] [Related]
2. Impact of the epoxide hydrolase EphD on the metabolism of mycolic acids in mycobacteria. Madacki J; Laval F; Grzegorzewicz A; Lemassu A; Záhorszká M; Arand M; McNeil M; Daffé M; Jackson M; Lanéelle MA; Korduláková J J Biol Chem; 2018 Apr; 293(14):5172-5184. PubMed ID: 29472294 [TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR Selectivity Analysis of 1-Adamantyl-3-Heteroaryl Urea Analogs as Potent Inhibitors of Mycobacterium tuberculosis. Wadhwa P; Bagchi S; Sharma A Curr Comput Aided Drug Des; 2015; 11(2):164-83. PubMed ID: 26234390 [TBL] [Abstract][Full Text] [Related]
5. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Brown JR; North EJ; Hurdle JG; Morisseau C; Scarborough JS; Sun D; Korduláková J; Scherman MS; Jones V; Grzegorzewicz A; Crew RM; Jackson M; McNeil MR; Lee RE Bioorg Med Chem; 2011 Sep; 19(18):5585-95. PubMed ID: 21840723 [TBL] [Abstract][Full Text] [Related]
8. The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. Biswal BK; Morisseau C; Garen G; Cherney MM; Garen C; Niu C; Hammock BD; James MN J Mol Biol; 2008 Sep; 381(4):897-912. PubMed ID: 18585390 [TBL] [Abstract][Full Text] [Related]
9. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. Grzegorzewicz AE; Korduláková J; Jones V; Born SE; Belardinelli JM; Vaquié A; Gundi VA; Madacki J; Slama N; Laval F; Vaubourgeix J; Crew RM; Gicquel B; Daffé M; Morbidoni HR; Brennan PJ; Quémard A; McNeil MR; Jackson M J Biol Chem; 2012 Nov; 287(46):38434-41. PubMed ID: 23002234 [TBL] [Abstract][Full Text] [Related]
10. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Phetsuksiri B; Baulard AR; Cooper AM; Minnikin DE; Douglas JD; Besra GS; Brennan PJ Antimicrob Agents Chemother; 1999 May; 43(5):1042-51. PubMed ID: 10223912 [TBL] [Abstract][Full Text] [Related]
11. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. Kim IH; Tsai HJ; Nishi K; Kasagami T; Morisseau C; Hammock BD J Med Chem; 2007 Oct; 50(21):5217-26. PubMed ID: 17894481 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Grzegorzewicz AE; Pham H; Gundi VA; Scherman MS; North EJ; Hess T; Jones V; Gruppo V; Born SE; Korduláková J; Chavadi SS; Morisseau C; Lenaerts AJ; Lee RE; McNeil MR; Jackson M Nat Chem Biol; 2012 Feb; 8(4):334-41. PubMed ID: 22344175 [TBL] [Abstract][Full Text] [Related]
13. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357 [TBL] [Abstract][Full Text] [Related]
14. The crystal structure of mycobacterial epoxide hydrolase A. Schulz EC; Henderson SR; Illarionov B; Crosskey T; Southall SM; Krichel B; Uetrecht C; Fischer M; Wilmanns M Sci Rep; 2020 Oct; 10(1):16539. PubMed ID: 33024154 [TBL] [Abstract][Full Text] [Related]
15. Expression and characterization of an epoxide hydrolase from Anopheles gambiae with high activity on epoxy fatty acids. Xu J; Morisseau C; Hammock BD Insect Biochem Mol Biol; 2014 Nov; 54():42-52. PubMed ID: 25173592 [TBL] [Abstract][Full Text] [Related]
16. Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Scherman MS; North EJ; Jones V; Hess TN; Grzegorzewicz AE; Kasagami T; Kim IH; Merzlikin O; Lenaerts AJ; Lee RE; Jackson M; Morisseau C; McNeil MR Bioorg Med Chem; 2012 May; 20(10):3255-62. PubMed ID: 22522007 [TBL] [Abstract][Full Text] [Related]